EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia

Nicola Dalbeth iD, Sarah Stewart iD, Gregory D Gamble, Borislav Mihov, Lisa K Stamp iD, Janine Haslett, William J Taylor iD, Tony R Merriman, Adwoa Dansoa Tabi-Amponsah iD, Anne Horne, Tuhina Neogi iD, Tristan Pascart iD und 8 weitere

Arthritis Care & Research · 2026-03 · 78 (3) · 417-423

DOI: 10.1002/acr.25639 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Care & Research, online erschienen am 26.11.2025. Verfasst von Nicola Dalbeth und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Hyperuricemia, Gout Suppressants, Uric Acid, Health Knowledge, Attitudes, Practice. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Horizon Pharmaceuticals, Simcere Pharma, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia.

Methods

Participants in a multinational study of asymptomatic hyperuricemia completed questionnaires about their perceptions of hyperuricemia, concern about hyperuricemia‐associated health conditions, and willingness to take urate‐lowering medication. All had a screening serum urate of ≥0.48 mmol/L (8 mg/dL) and no current or previous symptoms of gout.

Results

Overall, participants perceived that hyperuricemia had no or very few consequences on their life. Dietary factors were the most reported cause, whereas 37% did not know the cause. Participants reported a wide range in concern about hyperuricemia and the risk of developing gout. Concern about the risk of developing kidney disease or cardiovascular disease was also highly variable but was higher than concern about elevated serum urate ( P < 0.001). Most did not think a urate‐lowering medication was necessary, and there was moderate concern about the long‐term use of urate‐lowering medication. Medication necessity beliefs were most strongly associated with whether participants were willing to take urate‐lowering medication (partial R 2 = 0.27, P < 0.001).

Conclusion

Most participants perceived minimal consequences of asymptomatic hyperuricemia. Hyperuricemia was not well understood by participants, and biologic causes were generally underrecognized. Despite a range of concerns about hyperuricemia‐associated conditions, particularly kidney disease and cardiovascular disease, a urate‐lowering medication for asymptomatic hyperuricemia was not considered necessary, which aligns with most current management guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaGout SuppressantsUric AcidHealth Knowledge, Attitudes, PracticePerceptionHumansMaleFemaleMiddle AgedAsymptomatic DiseasesAgedAdultSurveys and QuestionnairesGout

Substanzen

Gout SuppressantsUric Acid

Autor:innen und Institutionen

  • University of Auckland, Auckland, New Zealand.
  • University of Otago Christchurch and Health New Zealand, Christchurch, New Zealand.
  • University of Otago Wellington, Wellington, New Zealand.
  • University of Otago Dunedin, Dunedin, New Zealand, and University of Alabama at Birmingham.
  • Boston University School of Medicine, Boston, Massachusetts.
  • Lille Catholic University, Lille, France.

ORCID-Profile: Nicola Dalbeth, Sarah Stewart, Lisa K Stamp, William J Taylor, Adwoa Dansoa Tabi-Amponsah, Tuhina Neogi, Tristan Pascart, Mariano Andrés, Till Uhlig, Changgui Li, Keith J Petrie

Förderung

  • Horizon Pharmaceuticals
  • Simcere Pharma
  • NIH HHS
  • Auckland Medical Research Foundation
  • National Key Research and Development Program of China
  • Health Research Council of New Zealand
  • National Institutes of Health

Zitieren

APA

Dalbeth, N., Stewart, S., Gamble, G. D., Mihov, B., Stamp, L. K., Haslett, J., Taylor, W. J., Merriman, T. R., Tabi-Amponsah, A. D., Horne, A., Neogi, T., Pascart, T., Andrés, M., Peral-Garrido, M. L., Norkuviene, E., Vazquez-Mellado, J., Uhlig, T., Sun, M., Li, C., & Petrie, K. J. (2026). Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia. Arthritis Care & Research, 78(3), 417-423. https://doi.org/10.1002/acr.25639

Vancouver

Dalbeth N, Stewart S, Gamble GD, Mihov B, Stamp LK, Haslett J, et al. Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia. Arthritis Care & Research. 2026;78(3):417-423. doi:10.1002/acr.25639

BibTeX
@article{Dalbeth2026,
  author = {Dalbeth, Nicola and Stewart, Sarah and Gamble, Gregory D and Mihov, Borislav and Stamp, Lisa K and Haslett, Janine and Taylor, William J and Merriman, Tony R and Tabi-Amponsah, Adwoa Dansoa and Horne, Anne and Neogi, Tuhina and Pascart, Tristan and Andrés, Mariano and Peral-Garrido, Maria-Luisa and Norkuviene, Eleonora and Vazquez-Mellado, Janitzia and Uhlig, Till and Sun, Mingshu and Li, Changgui and Petrie, Keith J},
  title = {Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia},
  journal = {Arthritis Care & Research},
  year = {2026},
  volume = {78},
  number = {3},
  pages = {417--423},
  doi = {10.1002/acr.25639}
}
Kostenlos starten →